» Articles » PMID: 22508047

CB1 Cannabinoid Receptor Activation Rescues Amyloid β-induced Alterations in Behaviour and Intrinsic Electrophysiological Properties of Rat Hippocampal CA1 Pyramidal Neurones

Overview
Date 2012 Apr 18
PMID 22508047
Citations 29
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Amyloid beta (Aβ) is believed to be responsible for the synaptic failure that occurs in Alzheimer's disease (AD), but there is little known about the functional impact of Aβ on intrinsic neuronal properties. Here, the cellular effect of Aβ-induced neurotoxicity on the electrophysiological properties of CA1 pyramidal neurons and the mechanism(s) of neuroprotection by CB1 cannabinoid receptor activation was explored.

Methods: A combination of behavioural, molecular and electrophysiological approaches was used.

Results: Bilateral injections of the Aβ peptide fragment (1-42) into the prefrontal cortex caused a significant impairment in the retention and recall capability in the passive avoidance tasks and significantly increased the level of active caspase-3 in the hippocampus. Whole-cell patch clamp recordings revealed a significant reduction in the intrinsic action potential (AP) frequency and an increase in the discharge irregularity in the absence of synaptic inputs in Aβ treated group. Aβ treatment induced also significant changes in both the spontaneous and evoked neuronal responses. However, co-treatment with ACEA, a CB1 receptor agonist, preserved almost the normal intrinsic electrophysiological properties of pyramidal cells.

Conclusions: In vivo Aβ treatment altered significantly the intrinsic electrophysiological properties of CA1 pyramidal neurons and the activation of CB1 cannabinoid receptors exerted a strong neuroprotective action against Aβ toxicity.

Citing Articles

Exploring the diversity of cannabis cannabinoid and non-cannabinoid compounds and their roles in Alzheimer's disease: A review.

Doumar H, Mostafi H, Elhessni A, Touhami M, Mesfioui A IBRO Neurosci Rep. 2025; 18:96-119.

PMID: 39866750 PMC: 11763173. DOI: 10.1016/j.ibneur.2024.12.011.


Potential Therapeutic Targets to Modulate the Endocannabinoid System in Alzheimer's Disease.

Kanwal H, Sangineto M, Ciarnelli M, Castaldo P, Villani R, Romano A Int J Mol Sci. 2024; 25(7).

PMID: 38612861 PMC: 11012768. DOI: 10.3390/ijms25074050.


The Therapeutic Potential and Molecular Mechanisms Underlying the Neuroprotective Effects of Sativex - A Cannabis-derived Spray.

Motamedy S, Soltani B, Kameshki H, Kermani A, Saboori Amleshi R, Nazeri M Mini Rev Med Chem. 2024; 24(15):1427-1448.

PMID: 38318827 DOI: 10.2174/0113895575285934240123110158.


Exploring the therapeutic potential of natural compounds modulating the endocannabinoid system in various diseases and disorders: review.

Wilson G, Yang L, Su X, Ding S, Li L, Yang Y Pharmacol Rep. 2023; 75(6):1410-1444.

PMID: 37906390 DOI: 10.1007/s43440-023-00544-7.


Deleterious and protective effects of epothilone-D alone and in the context of amyloid β- and tau-induced alterations.

Robles-Gomez A, Ordaz B, Lorea-Hernandez J, Pena-Ortega F Front Mol Neurosci. 2023; 16:1198299.

PMID: 37900942 PMC: 10603193. DOI: 10.3389/fnmol.2023.1198299.